TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34436552

Group type: EXPERIMENTAL
Intervention: Reach Plus Message
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Reach Plus Phone
Number of subjects: 161

Group type: COMPARATOR
Intervention: Reach Plus
Number of subjects: 161
Study: 36274326

Group type: EXPERIMENTAL
Intervention: Hybrid comprehensive telerehabilitation (HCTR) for 9 weeks
Number of subjects: 773

Group type: COMPARATOR
Intervention: Usual care (UC) for 9 weeks
Number of subjects: 773

Group type: EXPERIMENTAL
Intervention: Hybrid comprehensive telerehabilitation (HCTR)
Number of subjects: 773
Study: 32006073

Group type: EXPERIMENTAL
Intervention: Endoscopic 2-incision operation with partial fasciotomy and heel spur removal followed by a controlled strength training program
Number of subjects: 30

Group type: COMPARATOR
Intervention: Non-operative treatment with corticosteroid injections and a controlled strength training program
Number of subjects: 30
Study: 36478142

Group type: EXPERIMENTAL
Intervention: BI 187004 (20, 80 or 240 mg) as monotherapy
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: BI 187004 (240 mg) in combination with metformin
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: BI 187004 treatment
Number of subjects: 103
Study: 34081076

Group type: EXPERIMENTAL
Intervention: apalutamide+ADT
Number of subjects: 233

Group type: COMPARATOR
Intervention: placebo+ADT
Number of subjects: 233
Study: 32841523

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILI) aimed at weight loss
Number of subjects: 4859

Group type: COMPARATOR
Intervention: Diabetes support and education (DSE)
Number of subjects: 4859

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILI)
Number of subjects: 4859
Study: 32773602

Group type: EXPERIMENTAL
Intervention: Alpha-lipoic acid (ALA), median maximal tolerated dose 1663 mg/day
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Alpha-lipoic acid (ALA)
Number of subjects: 27
Study: 33198767

Group type: EXPERIMENTAL
Intervention: ENhanced Recovery In CHildren Undergoing Surgery (ENRICH‐US) intervention
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: ENHANCED RECOVERY PROTOCOL
Number of subjects: 18
Study: 34057707

Group type: EXPERIMENTAL
Intervention: PRC-063 (all doses combined)
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: PRC-063 (open-label extension)
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: PRC-063 (double-blind treatment)
Number of subjects: 297

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 297
Study: 35534443

Group type: EXPERIMENTAL
Intervention: Lactobacillus complex capsules (probiotics group)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Enteric-coated aspirin only (control group)
Number of subjects: 69
Study: 32875383

Group type: EXPERIMENTAL
Intervention: DEX 8 mg plus ETO 300 mg (DEX + ETO)
Number of subjects: 60

Group type: COMPARATOR
Intervention: DEX 8 mg (DEX)
Number of subjects: 60

Group type: COMPARATOR
Intervention: ETO 300 mg (ETO)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (Paracetamol 750 mg as rescue analgesics)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 60
Study: 35409460

Group type: EXPERIMENTAL
Intervention: Masticatory Muscle Training (MaMuT) - part 1: three physiotherapeutic treatments and daily home exercises; part 2: daily home exercises only
Number of subjects: 3

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 3
Study: 32613281

Group type: EXPERIMENTAL
Intervention: Ixazomib
Number of subjects: 656

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 656
Study: 34310044

Group type: EXPERIMENTAL
Intervention: Mediterranean-like diet (Med-diet)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Western-like diet (West-diet)
Number of subjects: 87
Study: 33045886

Group type: EXPERIMENTAL
Intervention: EtCO2: 26 − 35 mmHg (Group A)
Number of subjects: 60

Group type: COMPARATOR
Intervention: EtCO2: 36 − 45 mmHg (Group B)
Number of subjects: 60
Study: 35851507

Group type: EXPERIMENTAL
Intervention: High-dose Vitamin B6 supplementation
Number of subjects: 478

Group type: EXPERIMENTAL
Intervention: High-dose Vitamin B12 supplementation
Number of subjects: 478

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 478
Study: 33819750

Group type: EXPERIMENTAL
Intervention: HIPEC with standard of care
Number of subjects: 432

Group type: COMPARATOR
Intervention: Standard of care without HIPEC
Number of subjects: 432
Study: 35797643

Group type: EXPERIMENTAL
Intervention: Single-Dermatome Laparoscopic Appendectomy (SDLA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard Laparoscopic Appendectomy (SLA)
Number of subjects: 0
Study: 33813962

Group type: EXPERIMENTAL
Intervention: Sclerotherapy + low energy percutaneous RF thermocoagulation
Number of subjects: 111

Group type: COMPARATOR
Intervention: Sclerotherapy alone
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Sclerotherapy + RF thermocoagulation
Number of subjects: 111
Study: 32899045

Group type: EXPERIMENTAL
Intervention: Qishe pill
Number of subjects: 330
Study: 33675351

Group type: EXPERIMENTAL
Intervention: High-dose FA (4.0 mg daily)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Low-dose FA (≤1.1 mg daily)
Number of subjects: 50
Study: 36401223

Group type: EXPERIMENTAL
Intervention: Lower BW (≤ 2500 g)
Number of subjects: 4005

Group type: EXPERIMENTAL
Intervention: Normal BW (2500 g < BW ≤ 3500 g)
Number of subjects: 4005

Group type: EXPERIMENTAL
Intervention: Higher BW (> 3500 g)
Number of subjects: 4005
Study: 32040379

Group type: EXPERIMENTAL
Intervention: Quadrivalent cell-based influenza vaccine (QIVc)
Number of subjects: 2500000
Study: 32741231

Group type: EXPERIMENTAL
Intervention: Arm sling
Number of subjects: 57

Group type: COMPARATOR
Intervention: No arm sling
Number of subjects: 57
Study: 32343211

Group type: EXPERIMENTAL
Intervention: Tablet-based ultrasound (US) for assessing bone age
Number of subjects: 128
Study: 36329602

Group type: EXPERIMENTAL
Intervention: 15 g of almond paste and 4 g of inulin
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Co-ingestion of almond paste with bread
Number of subjects: 15
Study: 32430429

Group type: EXPERIMENTAL
Intervention: Total antibody (Ab)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: IgM
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: IgG
Number of subjects: 80
Study: 36171245

Group type: EXPERIMENTAL
Intervention: Facebook advertisement in native language (Arabic, Turkish, Russian)
Number of subjects: 888994

Group type: EXPERIMENTAL
Intervention: Facebook advertisement using government representatives as messengers
Number of subjects: 888994

Group type: EXPERIMENTAL
Intervention: Facebook campaign overall
Number of subjects: 888994
Study: 34085474

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) at Neiguan (PC 6) 30 min before anesthesia induction until the end of surgery
Number of subjects: 60

Group type: COMPARATOR
Intervention: General anesthesia and one-lung ventilation (OLV)
Number of subjects: 60
Study: 34928529

Group type: EXPERIMENTAL
Intervention: ProTaper Universal Retreatment (PTUR) without solvent
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: ProTaper Universal Retreatment (PTUR) with solvent
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: XP‐endo systems without solvent
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: XP‐endo systems with solvent
Number of subjects: 12
Study: 33414406

Group type: EXPERIMENTAL
Intervention: 3 g tryptophan (Trp-3)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 1.5 g tryptophan (Trp-1.5)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (0.9% saline)
Number of subjects: 12
Study: 36301337

Group type: EXPERIMENTAL
Intervention: Stimulation of the entire lower limbs
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Stimulation of the quadriceps muscle
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control condition (no intervention)
Number of subjects: 12
Study: 34847915

Group type: EXPERIMENTAL
Intervention: Core stabilization exercises (CSE)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Strengthening exercise (STE)
Number of subjects: 36
Study: 34180838

Group type: EXPERIMENTAL
Intervention: Oral care protocol implemented by GPs and nurse practitioners
Number of subjects: 764
Study: 34739082

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) therapy
Number of subjects: 3965

Group type: COMPARATOR
Intervention: Eligibility criteria of RCTs
Number of subjects: 3965

Group type: COMPARATOR
Intervention: Eligibility criteria excluding patients
Number of subjects: 3965
Study: 32843213

Group type: EXPERIMENTAL
Intervention: Comprehensive functional rehabilitation programme
Number of subjects: 113
Study: 35295321

Group type: EXPERIMENTAL
Intervention: Diet P (high polyunsaturated fat diet)
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Diet M (high monounsaturated fat diet)
Number of subjects: 319
Study: 33611897

Group type: EXPERIMENTAL
Intervention: EXCROSSAL stent
Number of subjects: 833
Study: 35653611

Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention
Number of subjects: 135

Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 135
Study: 33607958

Group type: EXPERIMENTAL
Intervention: Royal Guard® LLIN (alpha‐cypermethrin + pyriproxyfen)
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Interceptor G2® LLIN (alpha‐cypermethrin + chlorfenapyr)
Number of subjects: 1500

Group type: COMPARATOR
Intervention: Interceptor® LLIN (alpha‐cypermethrin only)
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: All arms (including control)
Number of subjects: 1500
Study: 32570199

Group type: EXPERIMENTAL
Intervention: Asymmetry group (TGA)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Symmetric controls
Number of subjects: 44

Group type: COMPARATOR
Intervention: Normative controls
Number of subjects: 44
Study: 36001498

Group type: EXPERIMENTAL
Intervention: XEN gel stent
Number of subjects: 282

Group type: COMPARATOR
Intervention: NPDS
Number of subjects: 282
Study: 33377980

Group type: EXPERIMENTAL
Intervention: Remote activity monitoring (RAM) system; details on dosage and duration not available.
Number of subjects: 0
Study: 32551912

Group type: COMPARATOR
Intervention: Control diet containing background Se only (0.189 mg/kg; C)
Number of subjects: 560

Group type: EXPERIMENTAL
Intervention: Low level sodium selenite (0.376 mg/kg; LSS)
Number of subjects: 560

Group type: EXPERIMENTAL
Intervention: High level sodium selenite (0.558 mg/kg; HSS)
Number of subjects: 560

Group type: EXPERIMENTAL
Intervention: Low level commercial B Traxim® Se (0.244 mg/kg; LBT)
Number of subjects: 560

Group type: EXPERIMENTAL
Intervention: High level B Traxim® Se (0.448 mg/kg; HBT)
Number of subjects: 560

Group type: EXPERIMENTAL
Intervention: Low level selenised yeast (0.290 mg/kg; LSY)
Number of subjects: 560

Group type: EXPERIMENTAL
Intervention: High level selenised yeast (0.487 mg/kg; HSY)
Number of subjects: 560
Study: 34549635

Group type: EXPERIMENTAL
Intervention: Community Health Worker (CHW) outreach
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Community Health Worker (CHW) engagement
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Facilitators of CHW outreach and engagement
Number of subjects: 12
Study: 36195687

Group type: EXPERIMENTAL
Intervention: pepinemab antibody blockade of SEMA4D
Number of subjects: 0

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study: 34462906

Group type: EXPERIMENTAL
Intervention: Outpatient Foley catheter induction
Number of subjects: 163

Group type: COMPARATOR
Intervention: Inpatient Foley catheter induction
Number of subjects: 163
Study: 34958374

Group type: COMPARATOR
Intervention: Refined wheat flour (reference meal)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: WG wheat and lentil flour (WG-wheat-lentil)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: WG wheat and chickpea flour (WG-wheat-chickpeas)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: WG oat flour (WG-oat)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: WG oat flour with ferrous bisglycinate (WG-oat-FeBG)
Number of subjects: 30
Study: 34555149

Group type: EXPERIMENTAL
Intervention: Ibrexafungerp 300 mg BID for 1 day
Number of subjects: 186

Group type: COMPARATOR
Intervention: Fluconazole 150 mg for 1 day
Number of subjects: 186
Study: 32272888

Group type: EXPERIMENTAL
Intervention: In‐reach rehabilitation program (13 hours over 4 weeks)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Usual care (76% had GP consultation, 79% received physiotherapy, median of 1.96 hours over 4 weeks)
Number of subjects: 240
Study: 35990072

Group type: EXPERIMENTAL
Intervention: ABMT with real self-administered tDCS
Number of subjects: 80

Group type: COMPARATOR
Intervention: ABMT with sham self-administered tDCS
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: ABMT only
Number of subjects: 80

Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 80
Study: 33058745

Group type: EXPERIMENTAL
Intervention: PredictMed predictive model
Number of subjects: 102
Study: 35921643

Group type: EXPERIMENTAL
Intervention: Polypharmacy (use of >4 drugs daily)
Number of subjects: 1113
Study: 32899015

Group type: EXPERIMENTAL
Intervention: Ketamine/Propofol admixture (Group KP)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Propofol (Group P)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Ketamine/Propofol admixture (Group KP) and Propofol (Group P)
Number of subjects: 200
Study: 35818640

Group type: EXPERIMENTAL
Intervention: Flapless Surgery (FLS) with Delayed Loading (DL)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Immediate Loading (IL) regardless of surgery protocol
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Flapless Surgery (FLS)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Flapped Surgery (FPS)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Delayed Loading (DL)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Immediate Loading (IL)
Number of subjects: 74
Study: 33516082

Group type: EXPERIMENTAL
Intervention: Behavioral Activation for Primary Care (BA-PC)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 140
Study: 34759547

Group type: EXPERIMENTAL
Intervention: Fentanyl 2 µg/kg i.v.
Number of subjects: 62

Group type: COMPARATOR
Intervention: Nalbuphine 0.2 mg/kg i.v.
Number of subjects: 62
Study: 36027601

Group type: EXPERIMENTAL
Intervention: Higher loads (HL; 80‐90% 1RM)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Lower loads (LL; 30‐50% 1RM)
Number of subjects: 16
Study: 33494805

Group type: EXPERIMENTAL
Intervention: VR-assisted training (30 min) 5 days/week for 3 weeks
Number of subjects: 36

Group type: COMPARATOR
Intervention: Functional gait rehabilitation training (30 min) 5 days/week for 3 weeks
Number of subjects: 36
Study: 35197106

Group type: EXPERIMENTAL
Intervention: Mobile technology‐based intervention including a personalized website, Fitbit activity tracker and app, individually tailored text messages based on Fitbit data, and daily intervention content on Instagram for 6 months
Number of subjects: 200

Group type: COMPARATOR
Intervention: Fitbit activity tracker only for 6 months
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Mobile technology‐based intervention
Number of subjects: 200
Study: 36267092

Group type: EXPERIMENTAL
Intervention: Zhuyun formula (ZYF) with auricular acupressure for three months before ovarian stimulation
Number of subjects: 123

Group type: COMPARATOR
Intervention: Control group (waiting list for three months)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Zhuyun formula (ZYF) with auricular acupressure
Number of subjects: 123

Group type: COMPARATOR
Intervention: Control group (waiting list)
Number of subjects: 123
Study: 33369934

Group type: EXPERIMENTAL
Intervention: 0.3% sodium hyaluronate eye drops for 3 months
Number of subjects: 60

Group type: COMPARATOR
Intervention: Observation alone (control group)
Number of subjects: 60
Study: 34209600

Group type: EXPERIMENTAL
Intervention: Mediterranean/low carbohydrate (MED/LC) diet (n = 80)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Low fat (LF) diet (n = 79)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Both diet groups
Number of subjects: 159
Study: 32590999

Group type: EXPERIMENTAL
Intervention: Early Essential Newborn Care (EENC) implementation after training and coaching
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Facilitators for EENC implementation
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Barriers to EENC implementation
Number of subjects: 19
Study: 36194110

Group type: EXPERIMENTAL
Intervention: DBT plus SM
Number of subjects: 49762

Group type: COMPARATOR
Intervention: DM
Number of subjects: 49762
Study: 33536672

Group type: EXPERIMENTAL
Intervention: Timeliness of treatment initiation
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Factors associated with TI delay
Number of subjects: 237
Study: 35606135

Group type: EXPERIMENTAL
Intervention: Stepped-wedge cluster randomized trial (SW-CRT) design
Number of subjects: 17
Study: 33232658

Group type: EXPERIMENTAL
Intervention: 0.25% ropivacaine (R group)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 0.25% ropivacaine with 0.5 mcg/kg clonidine (RC group)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 0.25% ropivacaine with 0.1 mg/kg dexamethasone (RD group)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (R group)
Number of subjects: 45
Study: 33498704

Group type: EXPERIMENTAL
Intervention: Kinesio Taping (KT)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Sleeper Stretching (SS)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control
Number of subjects: 31
Study: 32411138

Group type: EXPERIMENTAL
Intervention: HIVIS-DNA/MVA-CMDR immunization regimen (HIVIS03)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Late MVA-CMDR boost (HIVIS06)
Number of subjects: 0
Study: 36126325

Group type: EXPERIMENTAL
Intervention: Honey
Number of subjects: 84

Group type: COMPARATOR
Intervention: Diphenhydramine
Number of subjects: 84
Study: 33900360

Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 66

Group type: COMPARATOR
Intervention: Community Weight Management (CWM) intervention
Number of subjects: 66
Study: 32608944

Group type: EXPERIMENTAL
Intervention: Orthodontic manual toothbrush (Professor Persin, «Spazzolificio Piave», Italy)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Ultrasonic toothbrush (Emmi‐dent, EMAG AG, Germany)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Electric toothbrush ("Oral‐B Pro‐Expert, «Procter & Gamble», USA)
Number of subjects: 63
Study: 33904591

Group type: EXPERIMENTAL
Intervention: Intent-to-attend scores
Number of subjects: 1056

Group type: EXPERIMENTAL
Intervention: Early attendance
Number of subjects: 1056

Group type: EXPERIMENTAL
Intervention: Baseline intent-to-attend scores
Number of subjects: 1056

Group type: COMPARATOR
Intervention: Baseline relationship satisfaction
Number of subjects: 1056

Group type: COMPARATOR
Intervention: Group assignment (treatment or wait-list control)
Number of subjects: 1056
Study: 34514598

Group type: EXPERIMENTAL
Intervention: Bamlanivimab 700 mg
Number of subjects: 2970

Group type: EXPERIMENTAL
Intervention: Etesevimab 1400 mg
Number of subjects: 2970

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2970
Study: 34252915

Group type: EXPERIMENTAL
Intervention: DFN-15 62.5 mg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: DFN-15 125 mg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: DFN-15 250 mg
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 33040141

Group type: EXPERIMENTAL
Intervention: Acute pain group
Number of subjects: 67

Group type: COMPARATOR
Intervention: Chronic pain group
Number of subjects: 67

Group type: COMPARATOR
Intervention: No pain group
Number of subjects: 67
Study: 32678786

Group type: EXPERIMENTAL
Intervention: One-pedal operation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional two-pedal operation
Number of subjects: 0
Study: 35842070

Group type: EXPERIMENTAL
Intervention: Parent-administered pediatric tuina
Number of subjects: 43
Study: 34107152

Group type: EXPERIMENTAL
Intervention: Total intravenous anaesthesia (TIVA) with propofol
Number of subjects: 84

Group type: COMPARATOR
Intervention: Sevoflurane (SEVO) inhaled anaesthesia
Number of subjects: 84
Study: 32424961

Group type: EXPERIMENTAL
Intervention: Craniotomy patients with intracranial infections (case group)
Number of subjects: 196

Group type: COMPARATOR
Intervention: Craniotomy patients without intracranial infections (control group)
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Risk factors identified for intracranial infection
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Trauma surgery
Number of subjects: 196
Study: 35507017

Group type: EXPERIMENTAL
Intervention: MEDI0680 (20 mg/kg) with durvalumab (750 mg)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Nivolumab (240 mg)
Number of subjects: 63
Study: 33834908

Group type: EXPERIMENTAL
Intervention: Progressive dilution of feed (10, 20, 30, and 40%) with cellulose fibre, rice husk, sand, vermiculite, or sawdust
Number of subjects: 189

Group type: COMPARATOR
Intervention: Ad libitum access to one of 21 maize-soyabean based feeds
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Trial data used to estimate maximum scaled feed intake (SFImax)
Number of subjects: 189
Study: 33883157

Group type: EXPERIMENTAL
Intervention: Workplace‐based HIV self‐testing
Number of subjects: 44

Group type: COMPARATOR
Intervention: COVID-19 restrictions
Number of subjects: 44

Group type: COMPARATOR
Intervention: COVID-19 pandemic
Number of subjects: 44
Study: 35227582

Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS) after a three-week induction treatment and six months of maintenance treatment (three-week periodicity)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 78
Study: 33938081

Group type: EXPERIMENTAL
Intervention: Polish surface treatment
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Optiglaze surface treatment
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Wine immersion (both Polish and Optiglaze)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Polish surface treatment (all immersion liquids)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Optiglaze surface treatment (artificial saliva, tea, and wine)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Wine immersion (Polish and Optiglaze)
Number of subjects: 80